The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

Phase 2 Terminated 107 enrolled Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the efficacy of gefapixant (AF-219/MK-7264) in female participants with moderate to severe pain associated with interstitial cystitis/bladder pain syndrome (IC/BPS) after 4 weeks of treatment.

Timeline

Start: 2012-04-13
Primary completion: 2014-05-01
Completion: 2014-05-14

Publications

Imamura M, Scott NW, Wallace SA, Ogah JA, Ford AA, Dubos YA, Brazzelli M. Interventions for treating people with symptoms of bladder pain syndrome: a network meta-analysis. Cochrane Database Syst Rev. 2020 Jul 30;7(7):CD013325. doi: 10.1002/14651858.CD013325.pub2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gefapixant	Small molecule	50 mg	Oral
Subject	Gefapixant	Small molecule	100 mg	Oral
Subject	Gefapixant	Small molecule	150 mg	Oral
Subject	Gefapixant	Small molecule	200 mg	Oral
Subject	Gefapixant	Small molecule	250 mg	Oral
Subject	Gefapixant	Small molecule	300 mg	Oral

The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

Summary

Timeline

Publications

Drugs

Indications